



Universiteit
Leiden
The Netherlands

Juvenile Idiopathic Arthritis: Towards Improving Clinical Care

Hissink Muller, P.

Citation

Hissink Muller, P. (2019, October 31). *Juvenile Idiopathic Arthritis: Towards Improving Clinical Care*. Retrieved from <https://hdl.handle.net/1887/80001>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/80001>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/80001> holds various files of this Leiden University dissertation.

Author: Hissink Muller, P.

Title: Juvenile Idiopathic Arthritis: Towards Improving Clinical Care

Issue Date: 2019-10-31

1

General introduction

JUVENILE IDIOPATHIC ARTHRITIS

Juvenile idiopathic arthritis (JIA) is the collective name of diseases characterized by chronic arthritis commencing in the pediatric age. The first descriptions of the disease dates back to as far as 1864-1900¹. Initial organized attempts to classify the disease gave rise to the 1973 juvenile rheumatoid arthritis (JRA) criteria², hampered by difficulty of establishing criteria for a condition including more than one entity. In the years to follow important landmark meetings were held both in Europe and the United States: a new pediatric specialty was born. A new classification of Juvenile Chronic arthritis (JCA) by the European League against Rheumatism³ was adopted in 1978. The two sets of criteria differed, hindering to compare research data overseas. A new consensus classification was introduced⁴ which is currently still in use(see table 1). The umbrella term JIA is defined as any arthritis of unknown etiology with onset before the age of 16 years old and lasts for at least 6 weeks. Each category is mutually exclusive. In recent years systemic JIA has been recognized as an auto-inflammatory disease. This thesis focusses on patients with oligo-arthritis, polyarthritis and JIA with psoriasis.

The treatment of JIA consists of medical interventions and supportive care. In this thesis we focus on the medical treatment, supportive care is addressed in chapter 2.

Table 1 | International League of Associations for Rheumatology classification criteria for juvenile idiopathic arthritis in childhood

ILAR category	Characteristics	% of total
Systemic JIA	Arthritis and daily fevers ≥3 days, accompanied by at least one of the following: evanescent erythematous rash, generalised lymph node enlargement, hepato-/splenomegaly, serositis.	4-17
Oligoarticular	Arthritis in 1-4 joints during the first 6 months of disease	27-60
Persistent	Arthritis in 1-4 joints through the entire disease course	40
Extended	Arthritis in 5 of more joints after 6 months of disease	20
Polyarticular JIA RF+	Arthritis in 5 or more joints in the first 6 months of disease, at least two positive tests for rheumatoid factor at least 3 months apart.	2-7
Polyarticular JIA RF-	Arthritis in 5 or more joints in the first 6 months of disease, negative tests for rheumatoid factor.	11-30
Psoriatic JIA	Arthritis and psoriasis, or arthritis and at least 2 of the following: dactylitis, nailpitting or onycholysis, psoriasis in a first degree relative.	2-11
Enthesitis related Arthritis	Arthritis and enthesitis, or arthritis or enthesitis with at least 2 of the following: sacroiliac joint tenderness or inflammatory lumbosacral pain, HLA B27 antigen positive, onset in a boy> 8 years old, HLA B27 associated disease* in a first degree relative.	1-11
Undifferentiated JIA	Arthritis that does not fulfil criteria of one of the categories or meets criteria of more than 1 category.	11-21

*Ankylosing spondylitis, enthesitis related arthritis, sacro-iliitis with inflammatory bowel disease, Reiter's syndrome, or acute uveitis.

Antirheumatic drugs

Several drugs have been introduced for the medical treatment of patients with juvenile idiopathic arthritis. An overview of the most commonly used antirheumatic drugs is given here.

Medical treatment

Medical treatment for juvenile idiopathic arthritis was historically aiming at symptom relief and consisted after aspirin of non-steroidal anti-inflammatory drugs (NSAIDs) which became available in the seventies⁵. The first slow-acting antirheumatic drugs like penicillamine and hydroxychloroquine appeared in the eighties for use in children and proved not to be effective in JIA.⁶ Methotrexate (MTX) and to a lesser extent sulphasalazine (SSZ), were more successful and were registered for JIA in early nineties.^{7,8} Methotrexate is still considered corner stone treatment for several categories of JIA⁹.

Glucocorticoids are a therapeutic option for patients with non-systemic JIA in case of severe disease, as bridging therapy, while waiting for the response of systemic therapy, although evidence on its effectiveness is lacking⁹. Intra-articular steroids in the form of triamcinolonehexacetonide are effective and safe for the treatment of arthritis in children^{28,29}. Recently it was suggested in retrospective studies that multiple injections were able to induce remission in a proportion of patients^{30,31}.

Sulfasalazine is one of the first antirheumatic drugs especially designed for the treatment of rheumatoid arthritis (RA) after its proven effectiveness for inflammatory bowel disease. It is a well-established DMARD for patients with RA either as monotherapy or in combination¹⁰. Its effectiveness in oligo- and polyarticular JIA was amongst others demonstrated in a multicenter randomized placebo-controlled trial in the Netherlands in 1992-1999¹¹. A longterm follow-up study showed that the beneficial effects persist for many years⁸.

Methotrexate (MTX) is an effective disease-modifying anti rheumatic drug in children with JIA. At a dose of 10 mg/m²/week MTX has been shown to have a significant therapeutic advantage over placebo and an acceptable safety profile⁷. A plateau of efficacy is reached with parental administration of 15 mg/ m²/week¹². The response to MTX may be inadequate in some patients, even at higher dosages, and lack of tolerability limits its usefulness sometimes^{13,14}. Due to suspected increased bioavailability a subcutaneous dosing regime is advised at higher dosages^{15,16}. An initial robust response to MTX is predictive for a better long term outcome¹⁷. Remission rates vary greatly from 7-45%¹⁸⁻²⁰. Relapse rates before the year 2000 were quite high, over 50% although reported in small series^{21,22}. Foell et al studied the optimal moment to stop MTX in JIA patients in a retrospective analysis and did not see a difference in terms of flare frequency in case of longer MTX therapy (mean

3.8 vs mean 12.6 months)²³. This result was confirmed in a multicenter, 12 vs 6 months withdrawal MTX study. In both groups flare rate was almost 40% within 1 year despite longer treatment with MTX in the 12months group²⁴.

Hydroxychloroquine, an antimalarial, is known since the 1950s in the treatment of rheumatoid arthritis. It was first applied in a study in JIA patients in the eighties and proved ineffective⁶. It is one of the least potent antirheumatic drugs, but still in use as an adjunct to combination therapy in rheumatoid arthritis²⁵. Although the role of hydroxychloroquine as adjunct therapy has been subject of study²⁶, convincing evidence is still lacking and this remains subject of further study.




Figure 1 | The armamentarium of antirheumatic drugs available for the treatment of JIA. The evolution of biologic DMARDs in past decades revolutionized the therapeutic management of arthritis. However, although the number of variety of therapies available for use in paediatric rheumatology (excluding glucocorticoids and NSAIDs) is greater than ever, deciding on a treatment strategy has correspondingly increased in complexity. Whereas some therapies have been tested in high-quality paediatric studies, only some have received specific approval for use in children with rheumatology diseases, and such approval may also be limited to certain JIA categories. Additionally, some drugs approved in adult rheumatology have been recommended for use in JIA without EMA or FDA approval. *Therapies tested in high-quality paediatric studies. Abbreviations: CAPS, cryopyrin-associated autoinflammatory syndromes; cDMARD, conventional disease-modifying drug; EMA, European Medicines Agency; E-oJIA, extended oligoarticular juvenile idiopathic, arthritis; ERA, enthesitis-related arthritis; IL-1-RA, IL-1 receptor antagonist; JIA, juvenile idiopathic arthritis; oJIA, oligoarticular juvenile idiopathic arthritis; pJIA, polyarticular juvenile idiopathic arthritis; psA, psoriatic arthritis; sJIA, systemic juvenile idiopathic arthritis; TNFi, tumour necrosis factor inhibitor; yo, years old.

Figure from: *Management of juvenile idiopathic arthritis: hitting the target*
Nature Reviews Rheumatology 2015;11(5): 290-300 (With permission of Prof Dr D Foell)

Leflunomide, a reversible inhibitor of de novo pyrimidine synthesis, was studied in polyarticular JIA only in one open-label trial²⁷. ACR30 response criteria were met in the majority in the short and long term.

By the end of the last century a new category of medication appeared with the development of the biologicals.

Bioogic treatment in JIA: what do we know up to now?

Technical developments and better understanding of the disease process led to the development of monoclonal antibodies against an important cytokine in juvenile idiopathic arthritis, tumor necrosis factor-alpha, TNF- α .

Since the development of biologicals and the first use in juvenile idiopathic arthritis almost 2 decades have past. Initially the effectiveness of etanercept was established in severe treatment refractory JIA³²⁻³³.

Dedicated observational studies have taught us about the effectiveness and improved quality of life in JIA patients treated with anti-TNF³⁴⁻³⁶. The safety profile, both in the short and long term is good³⁷⁻⁴⁰. Prolonged use up to 5 or even 10 years is described^{34,38,41,42}, underscoring its effectiveness and tolerability. Growth in JIA patients seems to be restored in treatment with etanercept⁴³⁻⁴⁵. The efficacy does not change when etanercept is given in a once weekly dose⁴⁶.

Secondly adalimumab⁴⁷, infliximab⁴⁸ and biologicals with other modes of action were studied⁴⁹⁻⁵¹ and often subsequently approved in JIA treatment.

As the years are passing, biologicals are used more often and earlier in the disease course⁵². Their place in the treatment of patients with recently diagnosed JIA and their effectiveness compared to other aggressive treatment strategies has yet to be determined^{53,54}.

Bottom up or top down?

Although the medical treatment in JIA depends to a large extent on the category of JIA, improved disease outcome has been achieved by early and aggressive immunosuppressive treatment, instead of by a gradual add-on approach of medication in case of ongoing disease activity⁵⁵. The ultimate outcome is irrespective of the JIA category: destruction of joints resulting in severe incapacity can occur in children with oligoarticular JIA, while some children with severe polyarthritis at onset can easily reach inactive disease within weeks when responding to medication^{55,56}. Despite advances in treatment options and modalities during the last decade, a considerable number of children with JIA remain refractory to therapy⁵⁷. The overall outcome of JIA needs to be improved while children are still developing joint damage and/or limitations in daily functioning⁵⁸. Many patients with JIA continued to have active disease 10 years after onset, with persistence of active

disease into adulthood as well^{8,59}. In a longitudinal study by Wallace et al. evaluating 437 patients with JIA over a median follow-up of 7 years showed that during the entire course of the disease, the patients spent less than 35% of the time in a state of clinical remission off medication, regardless of the JIA subcategory⁶⁰. Ringold described in 2009 a cohort of patients who spent the majority of their follow up time in active disease⁶¹. These data highlight the urgent need for improved treatments in JIA that are capable of inducing extended periods of clinical remission off medication. It is unclear how to position the available drugs in JIA in daily practice. The traditional (bottom up) approach was to 'go low, go slow', aiming to avoid in part unknown side effects of the available drugs. This approach to drug treatment emphasizes the stepped use of one disease modifying antirheumatic drug (DMARD) at a time. When first-line agents such as nonsteroidal anti-inflammatory drugs (NSAID) failed after months "second-line", "slow-acting" or "DMARDs" such as antimalarial agents, sulfasalazine (SSZ), methotrexate (MTX) were considered. In the past years a shift to an earlier introduction and more aggressive combination (top down) therapy was seen although comparative trials of different combinations lacked in JIA at the start of this thesis. A too cautious approach can lead to undertreatment and permanent disability.

The current approach in 2009 to the treatment of children with oligoarticular JIA was to start with a NSAID and/or intra-articular glucocorticoids. When that is not effective, to add SSZ and/or MTX, Patients with extended oligoarticular JIA, Rf negative polyarticular JIA and psoriatic arthritis also usually start with a NSAID. When that is not effective SSZ and/or MTX are added. MTX first in a relatively low dose, next a higher dose, sometimes with prednisone bridging. Only for patients with polyarthritis who have shown to be MTX resistant or for those who do not tolerate MTX the TNF-blocking agents are available. Studies have shown this to be a very effective drug, both on clinical outcome measures and on radiological damage progression^{37,62}. In 2011 ACR recommendations were published to guide treatment for JIA⁹, discerning three levels of disease activity, low, moderate and high, by recognizing features of poor prognosis, like radiographic damage at presentation or involvement of hip or cervical spine.

Combination therapy

At the start of this thesis (2009) combination therapies were not commonly administered to JIA patients. In several trials, patients already treated with MTX receiving new biological therapies were treated with MTX as co-medication in varying percentages of patients^{50,63,64}. After the success of combination therapies in rheumatoid arthritis, studies on initial combination therapies were first described in 2011 and onwards, although in the recommendations by Beukelman⁹ no advice is formulated on non-biological DMARD combinations due to a lack of evidence.

The TREAT study, a randomized blinded placebo controlled trial and the ACUTE JIA trial, with a randomized open-label design, both used the combination of methotrexate and antiTNF: (etanercept in TREAT, infliximab in ACUTE). Both trials demonstrated that early use of a biological agent resulted in higher frequencies of inactive disease.

Window of opportunity

As shown in the BeSt study in rheumatoid arthritis patients^{65,66} it is likely that also in JIA a window of opportunity exists where the disease is most responsive to treatment and susceptible for permanent suppression. In several papers the existence of this window of opportunity in children with JIA was illustrated^{8,67}. When inactive disease can be achieved during an early phase, the opportunity arises to discontinue the treatment, thus shortening the time of exposure to possible side effects of drugs.

Discontinuation of anti-rheumatic drugs

What is known from literature about stopping treatments in JIA? As mentioned previously stopping methotrexate is feasible with the risk of flare approximately 40% irrespective of treatment continuation for 6 or 12 months²⁴. Tapering or stopping TNF inhibitors has been evaluated in several retrospective studies⁶⁸⁻⁷³ which were all published after the onset of the study serving as the basis of this thesis. Flare rates are overall high varying from 50-69%. In the large recent prospective cohort study from Guzman et al⁷⁴, flares occurred in over 50% of patients, although significant flares requiring additional treatment occurred within the first year after stopping therapy in 25%.

Monitoring of clinical response

By the end of the nineties the ACR Pedi improvement scores were published⁷⁵ to aid in standardization of the conduct and reporting of clinical trials and additionally to facilitate the physician to determine whether a patient responds adequately to therapy.

The JIA Core Outcome Variables consist of:

1. Physician Global Assessment of Disease Activity (10 cm Visual Analogue Scale (VAS))
2. Parent/patient global assessment of overall well-being (10 cm VAS)
3. Functional Ability (Childhood Health Assessment Questionnaire)
4. Number of Joints with Active Arthritis
5. Number of Joints with Limitation of Movement
6. Erythrocyte Sedimentation Rate ESR.

For efficacy assessment, patients will be evaluated as “improved” or “not improved” by comparing the values of core outcome variables at the post-dose assessment time points with baseline values.

Definition of Improvement in Juvenile Idiopathic Arthritis

JIA ACRPedi30/50/70/90 improvement is defined as 3 of any 6 core outcome variables improved by at least 30/50/70/90% from the baseline assessments, with no more than 1 of the remaining variables worsened by more than 30%.

The advantage of reporting outcome measures uniformly proofed beneficial in comparing clinical data. However the relative improvements does not reflect actual disease status and prevents comparison of disease activity between patients. Additionally it is not easy to use in daily practice.

JADAS score

Therefore more recently the Juvenile arthritis disease activity score (JADAS-71,-27, or-10) was developed and validated⁷⁶.

The scores of 4 domains are added:

1. Physician Global Assessment of Disease Activity (0-10 cm Visual Analogue Scale (VAS))
2. Parent/patient global assessment of overall well-being (0-10 cm VAS)
3. Number of Joints with Active Arthritis (0-10 count of any involved joint, irrespective of its type, up to a maximum of 10 joints.
4. Normalized ESR; (ESR-20)/10; all values ESR above 120 are converted to 120, all values <20 are converted to 0.

To a maximum of 0-40 (JADAS-10) 0-57 (JADAS-27) and 0-101 (JADAS-71).

Since then adjustments were developed to a 3-point score, which facilitates use in a daily clinic because it is not necessary to wait for the sedimentation rate to determine the disease activity score⁷⁷. Cut-off values for various disease states are available for use in clinical trials^{78,79}.

Definition of inactive disease in Juvenile Idiopathic arthritis

Wallace defined inactive disease in 2004⁸⁰ which was adopted in the study design of the BeSt for Kids study: Inactive disease is characterized by criteria: no clinical symptoms of active synovitis; no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA; no active uveitis; normal ESR and/or CRP; Physician's global assessment of disease activity indicates no active disease. In addition to this definition the duration of morning stiffness of ≤ 15 minutes was added as criterion for inactive disease in 2011.⁸¹

Child Health Assessment Questionnaire

The Child Health Assessment Questionnaire is a measure of functional status, which is disease specific for JIA^{82,83}. Both disability and discomfort are tested focused on physical functioning. Eight domains are tested including dressing, grooming, eating and different general physical abilities divided over 30 items questioning difficulty in performance. The CHAQ score is calculated as the mean of the 8 functional areas. The final score is 0-3. Values of 0.13, 0.63, and 1.75 have previously been described to represent respectively mild, mild to moderate, and moderate disability⁸⁴. A change in score of 0.13 represents an important change in clinical status^{84,85}. The test is easy to use and short, therefore increasingly used in clinical trials as well as longitudinal studies. The test is characterized by good reliability and validity, as well as good discriminative properties and reasonable responsiveness⁸⁶.

Monitoring of radiographic damage

Over the years several scoring systems for assessing joint damage and progression have been developed⁸⁷. Since in children growing joints change anatomically over time, it is not easy to determine cartilage loss and erosions. This unique feature of growth in children limits the use of the most well-known scoring system from adult rheumatology: the Sharp-van der Heijde score in its original form⁸⁸. A pediatric adaptation (adding 5 areas in the wrist and omitting to score the feet, since foot joints are rarely involved in JIA) to the Sharp-van der Heide score was developed and validated⁸⁹ and has been used, although few, ever since^{90,91}. The older and more easy to perform Poznanski score⁹² is a measure of the ratio between carpo: metacarpal length and reflects the amount of radiographic damage in the wrist. Poznanski scores that are more negative represent more severe radiographic damage^{62,93-96}.

Which target are we aiming at?

Classically the ACRpedi30% was regarded as the clinical target in studies⁷⁵, reflecting 30% improvement in at least 3 out of 6 core set variables, with no more than one of the remaining variables worsening by more than 30%. As such this target was used in several trials.^{32,97,98} Against the background of all improvements due to increasing therapeutic options, mainly the introduction of etanercept, this target was gradually regarded as too low. In trials as well as observational studies ACRpedi50 and 70% became alternative targets^{26,38}. In clinical care inactive disease was gradually recognized and mentioned as the target to aim at⁹⁹. It took some time however before inactive disease was chosen as the primary outcome measure in a JIA clinical trial, as was proven to be a realistic target in RA⁶⁵.

The BeSt for Kids study

Despite new therapeutic options, it is still unclear how and when a drug or combination of drugs should be introduced over time in patients with juvenile idiopathic arthritis. Previous studies focused on the comparison of one drug or the combination with another drug or combination. More relevant for clinical practice is what consecutive therapeutic steps should be taken when disease activity is insufficiently suppressed. Additionally with inactive disease as a therapeutic target, which strategy results in the best long term outcomes, with the least side effects? Should all patients be treated initially with a combination of antihreumatic drugs or biologic agents, or can they be reserved for patients who fail on initial monotherapy? There are concerns about the long-term safety of more aggressive approaches, especially about infections and malignancies although results up to today are reassuring. Financial restrictions preclude treatment of newly diagnose JIA patients with expensive TNF-antagonists in many countries.

Against this background, and after the success of the BeSt study in RA⁶⁵, the BeSt for Kids study was developed by a group of (pediatric) rheumatologists. In this study three treatment strategies are compared (figure 1 page 99).

- 1 Sequential monotherapy, starting with methotrexate or Sulphasalazine, thereafter increasing MTX dose or switching to MTX, thereafter adding etanercept (anti-TNF).
- 2 Initial combination therapy with methotrexate and prednisolone bridging therapy, thereafter increasing MTX dose, thereafter adding etanercept (anti-TNF).
- 3 Initial combination therapy with methotrexate and etanercept (anti-TNF).

For patients failing on their medication, the treatment protocol prescribed a number of subsequent treatment steps. The decision whether or not to adjust medication was made every three months based on ACRPedi50% after initial 3 months, and based on inactive disease from 6 months and onwards. To avoid bias, the joint examination was performed by a physiotherapist or research nurse who remained blinded for the allocated treatment group during the entire study period. If the target (ACRPedi50% or inactive disease) was not met, the treating physician immediately adjusted therapy by proceeding to the next step in the allocated treatment group. In the target was met for at least 3 (oligoarticular disease) or 6 (polyarticular disease) months, medication was tapered and stopped according to a predetermined protocol. To avoid overtreatment of patients with oligoarticular JIA especially in the arm with initially etanercept and methotrexate the required duration of inactive disease is chosen to be three months for those patients. This study combined three study questions in one study: 1 Can we achieve inactive disease, 2 can we taper and stop DMARD therapy and if we can, 3 what is the flare frequency?

JIA categories under study

Three categories of JIA will be studied: oligoarticular JIA (both with persistent and extended phenotype), RF-negative polyarticular JIA and juvenile psoriatic arthritis. Inclusion of children with extended oligoarticular JIA, RF-negative polyarticular JIA and juvenile psoriatic arthritis when they need a DMARD probably warrants no further discussion. We have chosen to also include children with persistent oligoarticular JIA that continue to have active synovitis despite treatment with NSAID's and/or intra-articular glucocorticoids, considering the fact that in these patients outcome is highly variable. Albers et al¹⁰⁰ in a cohort of patients with JIA reveal that the percentage of time with active disease in the first two years after diagnosis is an objective parameter of the course of disease and is highly variable in all JIA categories. Within each category of JIA, patients can have a wide range of duration of disease activity varying from a short duration of time with active disease to ongoing disease activity.¹⁰⁰ The incidence of the other categories of JIA, for instance RF-positive polyarticular JIA, is too low to allow stratification.

Outline of this Thesis

This thesis consists of two parts. The first part describes three studies related to pathogenesis of JIA and the second part describes the results of a treatment strategy study in JIA, the BeSt for Kids study.

Part One Aspects of Pathogenesis of JIA

First the pathogenesis of JIA is reviewed against the latest research novelties in **chapter 2**. One of our objectives was to discover the role of the newly recognized antibodies in rheumatoid arthritis, the anticarbamylated proteins. In **Chapter 3** anticarbamylated proteins were studied in a large cohort of JIA patients, combined from the ABC-register and the BeSt for kids cohort.

Novel in the pathogenesis of auto-immune diseases in general and JIA in particular is the possible role of the intestinal microbiome. One of the first (pilot) studies worldwide between the onset of JIA and the possible role of the composition of the microbiota was initiated in JIA patients generated from the BeSt for Kids cohort and will be described in **chapter 4**.

Part Two Treatment Strategies in JIA

The BeSt for Kids study serves as the basis for this thesis. In this single-blinded multicenter randomized 3-armed treatment strategy study sequential monotherapy with either Sulphasalazine or Methotrexate (arm 1) is compared to initial combination therapy with Methotrexate and prednisolone (arm 2), and with initial combination therapy with etanercept and MTX (arm 3). In **chapter 5.1** we describe the 3-months clinical results of the

three treatment strategies in early onset JIA. The long term (24 months) clinical outcome is set out in **chapter 5.2**. **Chapter 6** deals with the results of the radiological outcome of the BeSt for Kids study. An interview study was conducted to decipher aspects of clinical equipoise in the BeSt for Kids study, set out in **chapter 7**. As the study proceeded one patient was wrongly diagnosed and included in the BeSt for Kids study due to a JIA mimic. **Chapter 8** describes the disease course as the patient had to be excluded from the BeSt for Kids study, secondarily diagnosed as systemic polyarteritis nodosa (PAN). The general discussion is presented in **chapter 9** and the summary is given in **chapter 10**.

Notes

1. Schaller JG. The history of pediatric rheumatology. *Pediatr Res* 2005;58:997-1007.
2. Brewer EJ, Jr. New criteria for juvenile rheumatoid arthritis. *Tex Med* 1973;69:84-92.
3. PHN W. Special Meeting on: nomenclature and classification of arthritis in children. *The Care of Rheumatic Children In Munthe E (ed) 1978 47-50.*
4. Petty RE. Growing pains: the ILAR classification of juvenile idiopathic arthritis. *J Rheumatol* 2001;28:927-8.
5. Levinson JE, Baum J, Brewer E, Jr., Fink C, Hanson V, Schaller J. Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis. *J Pediatr* 1977;91:799-804.
6. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. *N Engl J Med* 1986;314:1269-76.
7. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. *N Engl J Med* 1992;326:1043-9.
8. van Rossum MA, van Soesbergen RM, Boers M, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. *Ann Rheum Dis* 2007;66:1518-24.
9. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res (Hoboken)* 2011;63:465-82.
10. Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. *Drugs* 2005;65:1825-49.
11. van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. *Arthritis Rheum* 1998;41:808-16.
12. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. *Arthritis Rheum* 2004;50:2191-201.
13. Bulatovic M, Heijstek MW, Verkaaik M, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. *Arthritis Rheum* 2011;63:2007-13.
14. van Dijkhuizen EH, Wulffraat NM. Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review. *Pediatr Rheumatol Online J* 2014;12:51.
15. Tukova J, Chladek J, Nemcova D, Chladkova J, Dolezalova P. Methotrexate bioavailability after oral and subcutaneous administration in children with juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2009;27:1047-53.
16. Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. *J Rheumatol* 2004;31:179-82.
17. Bartoli M, Taro M, Magni-Manzoni S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. *Ann Rheum Dis* 2008;67:370-4.
18. Takken T, Van der Net J, Helders PJ. Methotrexate for treating juvenile idiopathic arthritis. *Cochrane Database Syst Rev* 2001:CD003129.
19. Wallace CA. Methotrexate: more questions than answers. *J Rheumatol* 2000;27:1834-5.
20. Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. *J Rheumatol* 2000;27:1830-3.

21. Ravelli A, Viola S, Ramenghi B, Aramini L, Ruperto N, Martini A. Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis. *J Rheumatol* 1995;22:1574-6.
22. Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. *Pediatrics* 1997;100:994-7.
23. Foell D, Frosch M, Schulze zur WA, Vogl T, Sorg C, Roth J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? *Ann Rheum Dis* 2004;63:206-8.
24. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. *JAMA* 2010;303:1266-73.
25. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med* 1996;334:1287-91.
26. Tynjala P, Vahasalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. *Ann Rheum Dis* 2011;70:1605-12.
27. Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2005;52:554-62.
28. Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. *Rheumatology (Oxford)* 2004;43:1288-91.
29. Eberhard BA, Sison MC, Gottlieb BS, Ilowite NT. Comparison of the intraarticular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in treatment of juvenile rheumatoid arthritis. *J Rheumatol* 2004;31:2507-12.
30. Lanni S, Bertamino M, Consolaro A, et al. Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. *Rheumatology (Oxford)* 2011;50:1627-34.
31. Papadopoulou C, Kostik M, Gonzalez-Fernandez MI, et al. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. *Arthritis Care Res (Hoboken)* 2013;65:1112-20.
32. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. *N Engl J Med* 2000;342:763-9.
33. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. *Arthritis Rheum* 2003;48:218-26.
34. Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. *Rheumatology (Oxford)* 2012;51:1407-15.
35. Anink J, Prince FH, Dijkstra M, et al. Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register. *Rheumatology (Oxford)* 2015.
36. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. *Ann Rheum Dis* 2004;63:1638-44.
37. Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. *Rheumatol Int* 2008;28:1031-4.
38. Prince FH, Twilt M, ten CR, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. *Ann Rheum Dis* 2009;68:635-41.
39. Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. *Ann Rheum Dis* 2014;73:1114-22.

40. Windschall D, Muller T, Becker I, Horneff G. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis. *Clin Rheumatol* 2015;34:61-9.
41. Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. *Rheumatology (Oxford)* 2011;50:189-95.
42. Tynjala P, Vahasalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. *Ann Rheum Dis* 2009;68:552-7.
43. Uettwiller F, Perlberg J, Pinto G, et al. Effect of biologic treatments on growth in children with juvenile idiopathic arthritis. *J Rheumatol* 2014;41:128-35.
44. Schmeling H, Seliger E, Horneff G. Growth reconstitution in juvenile idiopathic arthritis treated with etanercept. *Clin Exp Rheumatol* 2003;21:779-84.
45. Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. *Arthritis Rheum* 2010;62:3259-64.
46. Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. *Rheumatology (Oxford)* 2009;48:916-9.
47. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. *N Engl J Med* 2008;359:810-20.
48. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2007;56:3096-106.
49. Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. *Mod Rheumatol* 2011.
50. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. *Lancet* 2008;372:383-91.
51. Horneff G, Klein A, Klotsche J, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. *Arthritis Res Ther* 2016;18:272.
52. Otten MH, Anink J, Prince FH, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. *Ann Rheum Dis* 2015;74:1379-86.
53. Quartier P. When should we use TNF antagonists in children with rheumatic disease? *Joint Bone Spine* 2007;74:1-3.
54. Zhao Y, Wallace C. Judicious use of biologicals in juvenile idiopathic arthritis. *Curr Rheumatol Rep* 2014;16:454.
55. Wallace CA. Current management of juvenile idiopathic arthritis. *Best Pract Res Clin Rheumatol* 2006;20:279-300.
56. Guillaume S, Prieur AM, Coste J, Job-Deslandre C. Long-term outcome and prognosis in oligoarticular-onset juvenile idiopathic arthritis. *Arthritis Rheum* 2000;43:1858-65.
57. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. *JAMA* 2011;306:2340-7.
58. Ravelli A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2004;22:271-5.
59. Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. *J Rheumatol* 2003;30:579-84.
60. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. *Arthritis Rheum* 2005;52:3554-62.
61. Ringold S, Seidel KD, Koepsell TD, Wallace CA. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. *Rheumatology (Oxford)* 2009;48:972-7.
62. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2008;26:688-92.

63. Horneff G, De BF, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. *Ann Rheum Dis* 2009;68:519-25.
64. Otten MH, Anink J, Spronk S, van Suijlekom-Smit LW. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. *Ann Rheum Dis* 2012.
65. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007;146:406-15.
66. Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. *J Rheumatol Suppl* 2007;80:25-33.
67. Albers HM, Wessels JA, van der Straaten RJ, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. *Arthritis Rheum* 2009;61:46-51.
68. Prince FH, Twilt M, Simon SC, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. *Ann Rheum Dis* 2009;68:1228-9.
69. Remesal A, J DEI, Merino R, Garcia-Consuegra J. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. *J Rheumatol* 2010;37:1970-1.
70. Baszis K, Garbutt J, Toib D, et al. Clinical outcomes after withdrawal of anti-tumor necrosis factor alpha therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. *Arthritis Rheum* 2011;63:3163-8.
71. Postepski J, Kobusinska K, Olesinska E, Osinska V, Opoka-Winiarska V. Clinical remission in juvenile idiopathic arthritis after termination of etanercept. *Rheumatol Int* 2013;33:2657-60.
72. Pratsidou-Gertsis P, Trachana M, Pardalos G, Kanakoudi-Tsakalidou F. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission. *Clin Exp Rheumatol* 2010;28:919-22.
73. Chang CY, Meyer RM, Reiff AO. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy. *Arthritis Care Res (Hoboken)* 2015;67:658-66.
74. Guzman J, Oen K, Huber AM, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. *Ann Rheum Dis* 2015.
75. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis
14. *Arthritis Rheum* 1997;40:1202-9.
76. Consolaro A, Ruperto N, Bazzo A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. *Arthritis Rheum* 2009;61:658-66.
77. McErlane F, Beresford MW, Baildam EM, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. *Ann Rheum Dis* 2013;72:1983-8.
78. Consolaro A, Schiappapietra B, Dalpra S, Calandra S, Martini A, Ravelli A. Optimisation of disease assessments in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2014;32:S-30.
79. Consolaro A, Ravelli A. Defining criteria for disease activity states in juvenile idiopathic arthritis. *Rheumatology (Oxford)* 2015.
80. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. *J Rheumatol* 2004;31:2290-4.
81. Wallace CA, Giannini EH, Huang B, Irtter L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)* 2011;63:929-36.
82. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. *Arthritis Rheum* 1994;37:1761-9.
83. Wulffraat N, van der Net JJ, Ruperto N, et al. The Dutch version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). *Clin Exp Rheumatol* 2001;19:S111-S5.
84. Dempster H, Porepa M, Young N, Feldman BM. The clinical meaning of functional outcome scores in children with juvenile arthritis. *Arthritis Rheum* 2001;44:1768-74.

85. Brunner HI, Klein-Gitelman MS, Miller MJ, et al. Minimal clinically important differences of the childhood health assessment questionnaire. *J Rheumatol* 2005;32:150-61.
86. Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. *Rheum Dis Clin North Am* 2007;33:389-402.
87. Doria AS, Babyn PS, Feldman B. A critical appraisal of radiographic scoring systems for assessment of juvenile idiopathic arthritis. *Pediatr Radiol* 2006;36:759-72.
88. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol* 2000;27:261-3.
89. Ravelli A, Ioseliani M, Norambuena X, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. *Arthritis Rheum* 2007;56:3087-95.
90. Selvaag AM, Kirkhus E, Tornqvist L, Lilleby V, Aulie HA, Flato B. Radiographic damage in hands and wrists of patients with juvenile idiopathic arthritis after 29 years of disease duration. *Pediatr Rheumatol Online J* 2017;15:20.
91. Giancane G, Pederzoli S, Norambuena X, et al. Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)* 2014;66:27-33.
92. Poznanski AK, Hernandez RJ, Guire KE, Bereza UL, Garn SM. Carpal length in children--a useful measurement in the diagnosis of rheumatoid arthritis and some congenital malformation syndromes. *Radiology* 1978;129:661-8.
93. Magni-Manzoni S, Rossi F, Pistorio A, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. *Arthritis Rheum* 2003;48:3509-17.
94. Cassone R, Falcone A, Rossi F, et al. Unilateral destructive wrist synovitis in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2004;22:637-42.
95. Viola S, Felici E, Magni-Manzoni S, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. *Arthritis Rheum* 2005;52:2092-102.
96. Magnani A, Pistorio A, Magni-Manzoni S, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. *J Rheumatol* 2009;36:628-34.
97. Silverman E, Spiegel L, Hawkins D, et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2005;52:554-62.
98. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. *N Engl J Med* 2005;352:1655-66.
99. Wallace CA. Developing standards of care for patients with juvenile idiopathic arthritis. *Rheumatology (Oxford)* 2010;49:1213-4.
100. Albers HM, Brinkman DM, Kamphuis SS, et al. Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)* 2010;62:204-12.

The first part of the paper discusses the importance of the research and the objectives of the study. It highlights the need for a comprehensive understanding of the subject matter and the role of the researcher in this process. The second part of the paper presents the methodology used in the study, including the data collection methods and the analysis techniques. The third part of the paper discusses the results of the study and the conclusions drawn from the findings. The fourth part of the paper discusses the implications of the study and the future research directions. The fifth part of the paper discusses the limitations of the study and the strengths of the research. The sixth part of the paper discusses the contributions of the study to the field of research. The seventh part of the paper discusses the ethical considerations of the study. The eighth part of the paper discusses the funding sources of the study. The ninth part of the paper discusses the acknowledgments of the study. The tenth part of the paper discusses the references of the study.